Can a Two-Drug combo outsmart Hard-to-Treat lymphoma?
NCT ID NCT07724782
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This early-phase trial is testing whether the experimental drug zeprumetostat, which blocks a protein called EZH2, can work together with either another targeted drug (golidocitinib) or a standard chemotherapy regimen (GemOx) to shrink tumors in people with a rare and aggressive blood cancer called peripheral T-cell lymphoma. The study enrolls adults whose lymphoma has returned or not responded to at least one prior treatment. Researchers are looking for the safest dose and whether the combinations can produce a meaningful response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zeprumetostat combined with either golidocitinib or gemcitabine plus oxaliplatin
- What this could lead to
- If successful, this could point toward a new treatment option for people with relapsed or refractory peripheral T-cell lymphoma.
- What could go wrong
- This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. The combination regimens may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTCL-NOS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.